NanoViricides ships NV-387 oral gummies to DR Congo for Phase II mpox trial

NanoViricides, Inc.

NanoViricides, Inc.

NNVC

0.00
  • NanoViricides shipped its NV-387 oral gummies to the Democratic Republic of Congo for a Phase II mpox treatment trial.
  • Results have not been presented; patient enrollment and dosing are expected to start in the coming weeks once site training is completed.
  • The study is set to assess whether NV-387 is safe and effective in mpox patients, with cases expected to be the more severe Clade I strain.
  • The shipment also positions NV-387 for potential repurposing in a proposed Phase II Ebola trial in the region, which has been accepted for response planning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606220930ACCESSWRNAPR_____1180194) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.